Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

December 28, 2016

(HealthDay)—For patients with Parkinson's disease (PD) receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, according to a study published online Dec. 27 in JAMA Neurology.

Andrew J. Lees, M.D., from University College London, and colleagues enrolled 427 with PD receiving who experienced signs of end-of-dose deterioration into a phase 3 trial. Participants were randomized to a 14- to 15-week -controlled trial (129 received 25-mg/day opicapone, 154 received 50-mg/day opicapone, and 144 received placebo). Of the 376 patients who completed the double-blind phase, 286 completed a one-year open-label phase in which all patients received opicapone.

The researchers found that the least squares mean change in off-time was −64.5 minutes for the placebo group, and −101.7 and −118.8 minutes for the 25- and 50-mg/day opicapone groups, respectively. For the 50-mg/day opicapone group, the adjusted difference versus placebo was significant (−54.3 minutes; P = 0.008); the difference was not significant for the 25-mg group (−37.2 minutes; P = 0.11). Throughout the open-label phase, the off-time reduction was sustained (−126.3 minutes at one-year end point).

"Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in mean daily off-time in levodopa-treated patients with PD and motor fluctuations, and this effect is maintained for at least one year," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including BIAL, which manufactures opicapone and funded the study.

Explore further: ABT-494 effective for patients with rheumatoid arthritis

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

ABT-494 effective for patients with rheumatoid arthritis

December 1, 2016

(HealthDay)—A novel selective JAK-1 inhibitor, ABT-494, is effective for rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) or to at least one anti-tumor necrosis factor (anti-TNF) agent, ...

Continued two percent daily testosterone safe, effective

October 24, 2016

(HealthDay)—Once-daily testosterone solution 2 percent (T-sol) is safe and improves sex drive and energy in men with androgen deficiency, according to a study published in the November issue of The Journal of Urology.

Rifaximin effective for repeat treatment of IBS with diarrhea

December 27, 2016

(HealthDay)—Repeat treatment with the nonsystemic antibiotic rifaximin is effective in patients with relapsing symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), according to a study published in the December ...

Inhaled levodopa may rapidly relieve Parkinson's symptoms

October 13, 2016

(HealthDay)—An inhaled version of the Parkinson's drug levodopa can help when patients experience symptoms between doses of the pill form of the medication, according to a study published in the Oct. 12 issue of Science ...

Tx response no different for migalastat, placebo in fabry's

August 12, 2016

(HealthDay)—For patients with Fabry's disease, the percentage of patients with response at six months does not differ for those treated with the oral pharmacologic chaperone migalastat or with placebo, according to a study ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.